Physicians' Academy for Cardiovascular Education

Antisense and Apo B Synthesis Inhibition

Slides (presentation) - Dec. 28, 2012

Antisense and Apo B Synthesis Inhibition
Apo B-100: Long-recognized as a Promising Target
Antisense Technology Provided a Method for Targeting Apo B
Antisense Drug Discovery Selectively Targets
Mipomersen – A 2nd Generation Antisense Drug
Mipomersen Crosses the Hepatocyte and Nuclear Membrane
Mechanism of Action RNase H-mediated Degradation of Target mRNA
Metabolism of Mipomersen Drug Metabolism and Disposition
Targeting Apo B Production Reduces Formation of VLDL
The Development of Mipomersen
Reductions in Total Cholesterol Correlate With Apo B mRNA in
Pharmacology Proof of Concept ApoB Inhibition
Phase 2: Hypercholesterolemia, Monotherapy
Mipomersen Significantly Reduced LDL-C in Statin-Intolerant Patients
Mipomersen Pharmacokinetic and Pharmacodynamic Properties
Mipomersen Summary of Phase 3 Clinical Studies
Phase 3 Extension Study
Phase 3 Extension Study Study Design
Phase 3 Extension Study Sustained Reduction of Atherogenic
Phase 3 Extension Study Safety Data
Phase 3 Extension Study Safety Summary
Phase 3 Long Term Extension Study Overall Summary
Emerging Therapies in Development